Kornimate/medical-research-clean huggingface dataset:
effects of anesthesia technique on endothelial function

Conditions: Endothelial Dysfunction; Ischemia Reperfusion; Oxidative Stress

Summary: the aim of this study was to compare the effects of two different anesthesia methods, general anesthesia and infraclavicular block, on oxidative stress and endothelial dysfunction in upper extremity forearm operations.this prospective study aims to determine the ideal anesthesia method for patients undergoing upper extremity forearm surgeries under tourniquet by comparing general anesthesia and infraclavicular block applications in terms of oxidative stress and ed related to ischemia-reperfusion injury.

pneumatic tourniquets are commonly used in orthopedic extremity surgeries to reduce surgical trauma and blood loss. when the tourniquet is released, it leads to the release of more free oxygen radicals than under physiological conditions, resulting in ischemia-reperfusion injury, oxidative stress, and endothelial dysfunction (ed). endothelial dysfunction is characterized by the imbalance between vasoactive substances such as nitric oxide (no) and endothelin, which regulate vascular tone by exerting vasodilatory and vasoconstrictive effects.during ischemia, xanthine oxidase (xo) derived from xanthine dehydrogenase is the main source of free oxygen radicals (for), including superoxide anion (o2-), hydrogen peroxide (h2o2), and hydroxyl anion (oh-). superoxide anion reacts with no to produce peroxynitrite (onoo-), a reactive oxygen derivative. free radicals affect unsaturated fatty acids in membranes, leading to the production of malondialdehyde (mda), which exerts cytotoxic effects on endothelial cells. increased production of for due to oxidative stress and dysfunction of antioxidant mechanisms result in protein carbonylation. protein carbonyl groups (pc) serve as indicators of severe oxidative damage and loss of protein function

Eligibility criteria:
inclusion criteria: * scheduled for upper extremity surgery using a pneumatic tourniquet * american society of anesthesiologists (asa) physical status classification i exclusion criteria: * under 18 or over 65 years of age * hypertension * diabetes mellitus * malignancy * cardiovascular disease history (congestive heart failure, myocardial infarction, venous thrombosis) * cerebrovascular disease history * liver/kidney dysfunction * pregnant or breastfeeding women * history of substance and tobacco use * history of extremity ischemia

Keywords: endothelial dysfunction ischemia reperfusion oxidative stress infraclavicular block general anesthesia
beta glucan's effect on pembrolizumab immunologic response in stage iii-iv melanoma

Conditions: Melanoma Stage III; Melanoma Stage IV

Summary: the purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

this is a clinical pilot study using oral beta-glucan on patients with advanced stage iii-iv melanoma without evidence of disease receiving adjuvant pembrolizumab. the aim is to see whether beta-glucan treatment in combination with pembrolizumab may provide augmented immunologic phenotypes such as decreased peripheral mdscs, enhanced t effector cell function, or enhanced cytokine production in the peripheral blood or plasm of enrolled subjects. secondary outcome measures will include clinical endpoints such as recurrence, progression free survival and overall survival.

Eligibility criteria:
inclusion criteria: * any patients with suspected (clinical) or definitive (tissue) diagnosis of stage iii-iv melanoma starting or continuing adjuvant pembrolizumab without active evidence of disease (ned). * must be treatment naïve or have had treatment no less than 6 months prior to enrollment * 18 years or older * must be able to take pills * ecog performance status of 0-3 * ability to understand and willingness to sign a written informed consent * members of all racial and ethnic groups are eligible for this study exclusion criteria: * history of hypersensitivity reactions attributed to beta-glucan * patients receiving continuous or other ongoing immunosuppressive therapy * uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately * patients with mucosal melanoma * patients with concurrent malignancy or recent history thereof
leicester tendon extracorporeal shockwave studies

Conditions: Tendinopathy

Summary: to assess whether the addition of extra-corporeal shockwave therapy (eswt) to a structured home-exercise programme has any additional benefit to patients with tendinopathies

this involves patients with one of 6 different defined chronic tendinopathies. these individual sites are run as discrete sub-studies, with randomisation n occurring within sub-study grouping

Eligibility criteria:
inclusion criteria: 1. patients age \>18 2. symptoms (typically pain / stiffness) of at least 12 weeks of one of the following sites / conditions: 1. plantar fasciitis 2. insertional achilles tendinopathy 3. mid-substance achilles tendinopathy 4. patella tendinopathy 5. trochanteric pain syndrome (gluteus medius insertional tendinopathy / trochanteric bursitis) 6. tennis elbow 3. referred for eswt (shockwave) within the sports medicine department 4. objective imaging of tendon / structure confirming diagnosis and excluding tear or other structural injury (us or mri acceptable) exclusion criteria: 1. patients with the normal exclusions for eswt - including pre-existing skin injury over tendon site, recent steroid injection (within 6 weeks of eswt starting), patients on anticoagulation, patients with haemophilia or other bleeding tendency, patients with current febrile illness 2. previous eswt treatment for the same condition
use of nerv's inline device as an early diagnostic method for anastomotic leak.

Conditions: Anastomotic Leak

Summary: nerv's early feasibility clinical trial is a first-in-human, multi-center, pre-market, non-randomized clinical trial intended to evaluate the safety and collect preliminary data necessary for the detection of clinical post-operative anastomotic/intraperitoneal leakages. nerv's inline device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. this allows the device to measure the ph and conductance of intraperitoneal fluids that typically get drained through peritoneal drains. the purpose of nerv's feasibility clinical trial is to collect ph and conductance readings by analyzing peritoneal drainage fluid. upon analyzing data collected from nerv's inline device a clinical model of ph and conductance will be created. the clinical model can then be used to determine if a complication is developing. for instance, boundaries (reading thresholds) can be established where if the signal goes outside the boundaries a complication could be identified. specifically the ability to detect a post-operative complication known as anastomotic leakage; which is a dreaded complication associated with abdominal surgeries; will be the main focus of the study.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years - male or female * subject understands and has voluntarily signed and dated informed consent form (icf) * subjects must be willing to comply with trial requirements * subject has a peritoneal drain attached post-surgery exclusion criteria: * plans that the subject will be discharged less than 8 hours post-surgery * involvement in the planning and conduct of the clinical investigation * subject is participating in another investigational drug or device study which would interfere with the endpoints and follow-ups of this study * subject is consuming steroid or anti-inflammatory medication
safety of genexol pm and carboplatin as first-line therapy in ovarian cancer

Conditions: Ovarian Cancer

Summary: to evaluate the safety profile of genexol pm combination with carboplatin for patients with newly diagnosed ovarian cancer. we hypothesized genexol pm can be safely administered to newly diagnosed ovarian cancer patients compared to conventional paclitaxel/carboplatin combination therapy. therefore, we will compare the prospective cohort with a historical comparison with patients administered paclitaxel/carboplatin and paclitaxel/carboplatin/bevacizumab combination therapy.


Eligibility criteria:
inclusion criteria: * age over 18 * patients consented to participate * pathologically diagnosed ovarian cancer figo stage ic-ivb * ecog 0-2 * patients with an expected survival of 3 months or more exclusion criteria: * history of paclitaxel or carboplatin hypersensitivity * inadequate bone marrow function (neutrophil\<1500/mm3, platelet \<100,000/mm3) * pregnancy or breast-feeding state * metachronous or synchronous malignancy * galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption patients with genetic problems * other patients who were judged difficult to be included in this investigation by the investigator in charge
frequency of fibromyalgia in patients with celiac disease

Conditions: Celiac Disease; Fibromyalgia

Summary: 950 / 5.000 çeviri sonuçları celiac disease is an autoimmune proximal small bowel disease that develops as a persistent intolerance to gluten-like gluten in cereals, mainly wheat gluten and other cereal proteins such as barley, rye, and oats in genetically susceptible individuals. fibromyalgia syndrome (fms) is a chronic musculoskeletal disease characterized by chronic widespread body pain, fatigue, morning stiffness, subjective swelling, sleep disturbance, intestinal problems, multiple somatic and cognitive problems, especially in the back, neck, shoulders and hips. in terms of intestinal symptoms, very similar findings can be observed between celiac disease and fibromyalgia. for this reason, the presence of celiac disease in fms patients has been investigated in many studies and its frequency has been found to be high. however, the frequency of fms in patients with celiac disease is not clear, and an overlooked diagnosis of fibromyalgia may leave many symptoms untreated.


Eligibility criteria:
inclusion criteria: patients who agreed to participate in the study, signed the informed consent form, had the cognitive capacity to fill in the questionnaires and scales, and were followed up with a diagnosis of celiac will be included. exclusion criteria: patients whose celiac diagnosis is uncertain, who do not agree to participate in the study, and who do not have sufficient cognitive capacity will be excluded from the study.
effect of diet on the microbiota / endoccanabinoidome axis in response to physical activity

Conditions: Diet Habit; Microbial Colonization; Activity, Motor

Summary: both the endocannabinoid system and the microbiome are highly conditioned by nutrition and physical activity, and have an interdependent, bidirectional relationship. we suggest studying the interleaving between the endocannabinoidome-microbiome axis and host metabolism under the combined effect of a diet and physical activity. more specificly, we will study the link between the impact of the diet on the intestinal microbiome and the endocannabinoid reaction after intense exercise.

aims of the study are to compare the impacts of two short 7-day contrasted nutritional interventions (the mediterranean diet (med) and the canadian diet (can)) on blood metabolites (endocannabinoids) after a maximal aerobic test. a 3 weeks washout between the two diets is planned. gut microbiome at each test will also be evaluated.

Eligibility criteria:
inclusion criteria: * women * 20-30 years old * healthy * jogging \>1h/week and \>3h/week of physical activity * bmi 18.5-25 exclusion criteria: * postmenopausal, pregnancy or lactation * pathology or medication * smoking * more than 7 alcohol consumption/week * food allergy, food intolerance or food aversion * important weight change in the last 6 months * antibiotics in the last 3 months * night worker * pathologies

Keywords: microbiome endocannabinoids
assessment of adverse events in a naive pediatric population treated with an antipsychotic

Conditions: Dissociative Disorders; Schizophrenia

Summary: we propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population. its purpose is to evaluate the incidence of adverse events related to the use of l antipsychotic drugs in children and adolescents with no history of taking such drugs. the inclusion criteria will be: (1) male or female inpatients, (2) aged from 6 to 18 years, (3) requiring antipsychotic treatment, (4) receiving antipsychotic drug for less than 28 days without taking antipsychotic before or with a history of antipsychotic over a maximum period of three consecutive months and discontinued for at least 6 months. therapeutic monitoring during the 12 month study period will include clinical assessments and laboratory testing. these assessments will be performed before treatment (at inclusion), and at 1, 3, 6, 9, 12 months after the introduction of the antipsychotic drug.

a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population

Eligibility criteria:
inclusion criteria: * male or female patients * aged from 6 to 18 years * in whom antipsychotic treatment is indicated * who have never been treated with antipsychotic medication (other than metoclopramide (primperan®) for pediatric indications) or with a history of antipsychotic over a maximum period of three consecutive months and discontinued for at least 6 months. . the non-inclusion criteria: * any the exclusion criteria: * refusal or withdrawal of consent by the patient or his/her parents.
postoperative pain score of laparoscopic gynecological surgeries

Conditions: Surgical Incision; Gynecologic Surgery; Postoperative Pain

Summary: in this study, it was aimed to compare the embryonic route, the umbilicus, and the sub-umbilicus incision in terms of postoperative pain scoring. for this purpose, in laparoscopic hysterectomies performed for benign reasons, it is planned to measure the pain score at the 8th hour and 1st day postoperatively in the umbilicus and subumbilical incision. visual analog scoring system will be used for pain scoring.

in this prospective randomized study, baskent university adana dr. turgut noyan application and research center for benign reasons (myomas that cause abnormal uterine bleeding, resistant to medical and hysterescopic surgery, treatment-resistant adenomyosis in which the uterus reaches 12 weeks of gestation, recurrent endometrial hyperplasia, endometriosis, stage 1 endometrial cancers that only underwent hysterectomy) in laparoscopic hysterectomies; at the entrance to the abdomen, it is planned to apply the umbilicus, which is the anatomical route, to some of the patients, and to the other part of the sub-umbilicus incision. it will be compared in terms of pain score on the 8th hour and 1st day after surgery. the minimum quorum for each group was determined by calculating 41 and taking a total of 82 patients. the simple randomization technique will be applied in the distribution to the study sets. based on the studies, it is thought that the anatomical path may be less painful.

Eligibility criteria:
inclusion criteria 1. patients who underwent laparoscopic hysterectomy for benign reasons 2. stage 1 endometrial cancers that only underwent hysterectomy exclusion criteria: 1. malign disorders 2. uterus larger than 12 weeks of gestation

Keywords: laparoscopic surgery umbilical incision postoperative pain score
cardiac magnetic resonance for asymptomatic type 2 diabetics with cardiovascular high risk (catch) - pilot study

Conditions: Diabetes Mellitus, Type 2; Coronary Artery Disease

Summary: the aim of this study is to determine the prevalence of myocardial ischaemia in asymptomatic high risk type 2 diabetic patients using stress cardiac mr and how many stress cardiac mr examinations are false positive.

asymptomatic coronary artery disease (cad) is highly prevalent (ie. 17-59%) in type 2 diabetic patients. in addition, cardiovascular disease remains the most common cause of death in type 2 diabetics. previous trials using coronary computed tomography angiograms (ccta) or nuclear myocardial perfusion imaging (mpi) to screen for asymptomatic coronary artery disease requiring intervention have been unsuccessful at reducing cardiovascular and all cause mortality when compared to optimised medical therapy where cardiovascular risk factors are treated in order to reduce cardiovascular complications. possible reasons for this include, the choice of imaging modality, the intervention chosen (eg. bare metal stents vs drug eluting stents), patient cohort (eg. all diabetics vs high risk diabetics). stress cardiac magnetic resonance (cmr) is ideally suited to assess this group of high risk patients as there is no radiation exposure and it allows a more complete analysis of the heart including the assessment of myocardial viability, cardiac systolic and diastolic function. the significance of this envisioned randomised controlled trial is firstly to investigate if stress cmr screening will reduce major adverse cardiovascular events including death. secondly, a study using stress cmr has never been performed.

Eligibility criteria:
inclusion criteria: * onset of type 2 diabetes at ≥30yrs old with no history of ketoacidosis * 60-80yrs old * framingham risk score ≥20% exclusion criteria: * angina pectoris or chest discomfort * stress test or coronary angiography within 2 years * previous myocardial infarction (mi) * previous coronary artery stenting or coronary artery bypass grafting * any clinical indication or contraindication for stress testing * any contraindication to stress cmr (eg. non-mri compatible devices) * contraindication to gadolinium based contrast agent (eg. renal impairment with an estimated glomerular filtration rate (gfr) \<30ml/min/1.73m2) * life expectancy \<2 years due to cancer or liver disease * contraindication to dual antiplatelet therapy * planned need for concomitant cardiac surgery * refusal or inability to sign an informed consent. * potential for non-compliance towards the requirements in the trial protocol * unable to cover the costs of percutaneous coronary intervention (pci) whether through government subsidies, etc

Keywords: stress cardiac magnetic resonance
obs'cerevance: french cohort of pediatric autoimmune cytopenia

Conditions: Immune Thrombocytopenia; Autoimmune Hemolytic Anemia; Evans Syndrome

Summary: from 2004, obs'cerevance is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : immune thrombocytopenia (itp), autoimmune hemolytic anemia (aiha), or evans syndrome (all bi or tri cytopenias). thanks to the collaboration of the 30 french pediatric hematologic centers, this cohort supports all of the rare disease centre cerevance (centre de référence national des cytopénies auto-immunes de l'enfant) missions for care, education and research. specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

immune thrombocytopenic purpura (itp) and autoimmune hemolytic anemia (ahai) are rare childhood diseases that involve autoimmune destruction of platelets and erythrocytes respectively. they may be associated with an even rarer entity, evans syndrome (es). these three conditions are referred to as autoimmune cytopenias (aic). in association with cai, patients may present with various immunopathological (im) manifestations such as lymphoproliferation, autoimmune autoimmune/autoinflammatory organ diseases that may be absent at the time of at the time of diagnosis of cai and develop during follow-up. since 2004, the cerevance reference center for childhood autoimmune cerevance has been coordinating a national prospective cohort of patients with pediatric-onset cai including over 1900 patients (data 05/2023). thanks to the collaboration of the 30 french pediatric hematologic centers, this cohort supports all of the rare disease centre cerevance (centre de référence national des cytopénies auto-immunes de l'enfant) missions for care, education and research. specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

Eligibility criteria:
inclusion criteria: * diagnosis of itp, aiha, evans syndrome * onset before the age of 18 exclusion criteria: * opposition of legal representative or to data collection
angiogram based fractional flow reserve ffrangio - a validation study

Conditions: CAD - Coronary Artery Disease

Summary: in the present study we aim at validating the computation of ffrangio values from the angiogram by comparing them to measured wire-based ffr values, in a larger scale and in a completely blinded manner. investigation of a wide range of users in various conditions may strengthen the reliability of the ffrangio measurements.


Eligibility criteria:
inclusion criteria: * male and female above 18 years old age which undergo ffr as part of their standard care * timi grade flow is equal to 3 * lvef larger than 45%. * subjects with multi-vessel coronary artery disease, with nstemi are allowed. exclusion criteria: * contraindicated for ffr examination or adenosine administration * stemi * cto * timi grade flow below 3 * arteries supplying akinetic or severe hypokinetic territories * prior cabg on the study vessel * left main stenosis, in-stent restenosis and collaterals * diffused atherosclerosis diseases and tandem lesions * aorto-ostial lesion
clinical effects of large segmental bone defects with 3d printed titanium implant

Conditions: Large Segmental Bone Defect

Summary: the investigators apply 3d printed titanium implant to treat bone defects. without using bone grafts and growth factors, the investigators anticipate the titanium implant alone can help bone reconstruction.

the investigators treat large segmental bone defects caused by three reasons, including trauma, infection and tumor. in this study, polyporous 3d printed titanium implant is applied to reconstruct the bone defects and the investigators will follow up patients' function and bone regeneration.

Eligibility criteria:
inclusion criteria: * bone defects caused by trauma or infection or tumor * the length of bone defect is more than 6cm * more than 18 years old exclusion criteria: * malignant tumor * patients with bad conditions failing to tolerate surgery
viral conjunctivitis treatment study

Conditions: Viral Conjunctivitis

Summary: the objective of this study is to determine the efficacy avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. the investigators hypothesize that patients treated with avenova® will have a quicker resolution of their ocular signs and symptoms of viral conjunctivitis compared with artificial tears.


Eligibility criteria:
inclusion criteria: * patients presenting to the bascom palmer eye institute * clinical diagnosis of viral conjunctivitis * symptoms less than 1 week duration exclusion criteria: * history of allergic conjunctivitis * history of herpetic eye disease * concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating) * immunocompromised / immunosuppressed patients * patients with hiv * pregnant women * prisoners * adults who are unable to provide consent